Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Management
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week

Latest news

Group By Ticker
Sort By
Newest | Oldest
Read More
1 minute read
  • Biotech
  • General
  • Government
  • Health Care
  • Large Cap
  • News
  • Regulations

Best-Selling Drugs by Bristol Myers, Pfizer, AbbVie Likely Candidates For US Price Negotiation

By Vandana Singh
Today, 5:24 PM
Bristol Myers Squibb & Co’s (NYSE:BMY) Eliquis, Pfizer Inc’s (NYSE:PFE) Ibrance, and AbbVie Inc’s (NYSE:ABBV) Imbruvica are expected to be among the ten…

ABBV

Read More
6 minute read
  • Entertainment
  • General
  • News
  • Sports

Super Bowl Commercials 2023: The Complete List Of Super Bowl LVII Ads And The Companies Behind Them

By Chris Katje
Today, 5:24 PM
Super Bowl LVII aired Sunday Feb. 12, 2023 and featured dozens of commercials advertising products and showcasing new movies and television shows. The commercials also featured many celebrity cameos and several reunions. Here’s a look at the complete list.

ALPMY

Read More
1 minute read
  • Analyst Color
  • Analyst Ratings
  • Biotech
  • General
  • Health Care
  • News
  • Penny Stocks
  • Price Target
  • Reiteration

Analyst Says Selecta Biosciences’ Gout Candidate Can Potentially Raise The Bar On Several Fronts

By Vandana Singh
Today, 5:24 PM
Canaccord Genuity has increased the price target for Selecta Biosciences Inc (NASDAQ:SELB) from $9 to $10 while maintaining the Buy rating ahead of…

ALPMF

Read More
1 minute read
  • Biotech
  • FDA
  • General
  • Health Care
  • News

Astellas’ Menopause Drug Under FDA Review

By Vandana Singh
Today, 5:24 PM
The FDA accepted Astellas Pharma Inc’s (OTC:ALPMF) menopause treatment for approval five months after the therapy hit a speed bump in…

ALPMF

Read More
1 minute read
  • Biotech
  • Contracts
  • General
  • Health Care
  • Movers
  • News
  • Penny Stocks
  • Trading Ideas

Sutro Biopharma Stock Surges On Cancer Treatment Pact

By Vandana Singh
Today, 5:24 PM
Astellas Pharma Inc (OTC: ALPMF) and Sutro Biopharma Inc (NASDAQ:STRO) announced a strategic collaboration and licensing agreement focused on the discovery and development of…

ALPMF

Read More
3 minute read
  • Biotech
  • Contracts
  • FDA
  • General
  • Health Care
  • M&A
  • Movers
  • News
  • Penny Stocks
  • Small Cap
  • Trading Ideas

The Daily Biotech Pulse: CHMP Backs AstraZeneca’s Breast Cancer Therapies, Ipsen Buys Epizyme, FDA Holds For Nuvation Bio, Astellas Studies

By Vandana Singh
Today, 5:24 PM
Here's a roundup of top developments in the biotech space over the last 24 hours:

ALPMF

Read More
1 minute read
  • Biotech
  • Contracts
  • General
  • Health Care
  • Movers
  • News
  • Small Cap
  • Trading Ideas

Twist Bioscience, Astellas Join Forces To Develop Cancer Targeting Antibodies

By Vandana Singh
Today, 5:24 PM
Twist Bioscience Corporation (NASDAQ:TWST) has entered into a research collaboration and exclusive option license agreement with Astellas Pharma Inc (OTC:ALPMF) to conduct research…

ALPMF

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • News

Astellas – Seagen’s Padcev Approved In Europe For Most Common Form Of Bladder Cancer

By Vandana Singh
Today, 5:24 PM
The 

ALPMF

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • News

Astellas Touts Safety Data For Phase 3 Menopause Drug, Sets Up US Filing

By Vandana Singh
Today, 5:24 PM
Astellas Pharma Inc (OTC:ALPMF) announced topline results from the Phase 3 SKYLIGHT 4 trial investigating the long-term safety of fezolinetant in…

ALPMF

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • News

Astellas Pharma – Seagen’s Enfortumab Shows 36% Pathologic Complete Response In Bladder Cancer Patients

By Vandana Singh
Today, 5:24 PM
Seagen Inc (NASDAQ: SGEN) and Astellas Pharma Inc (OTC: ALPMF) 

ALPMF

Posts navigation

1 2 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service